A Phase 1 interventional study of Sitravatinib and Tislelizumab in Advanced Solid Tumors, sponsored by BeiGene. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was an open-label, multicenter, non-randomized Phase 1b clinical trial for participants with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ovarian cancer (OC), or melanoma.
All participants received sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg intravenously (IV) once every 3 weeks until occurrence of progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor. Participants were enrolled according to their tumor type and prior anti-programmed cell death protein-1 (PD-1)/PD-L1 antibody treatment into the following cohorts:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitravatinib 120 mg was administered orally once daily in combination with tislelizumab 200 mg intravenously (IV) once every 3 weeks
Drug: Sitravatinib · Drug: Tislelizumab
Administered orally as a capsule
Also known as: MGCD516
Administered intravenously
Also known as: BGB-A317, Tevimbra
Number of Participants With Adverse Events (AEs)
Number of participants with treatment-emergent AEs (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs; TEAE was defined as an adverse event that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug(s) up to 30 days following last dose of study drug(s) or initiation of a new anticancer therapy, whichever occurs first.
Time frame: Up to approximately 4 years and 2 months
Objective Response Rate (ORR)
ORR is defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) as determined by the investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
Time frame: Up to approximately 4 years and 2 months
Duration of Response (DOR)
DOR is defined as the time from the first determination of an objective response until the first documentation of progressive disease, whichever comes first, as assessed by the investigator using RECIST v1.1. Results are reported for cohorts with responders, defined as CR or PR. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
Time frame: Up to approximately 4 years and 2 months
Disease Control Rate (DCR)
DCR is defined as the percentage of participants with best overall response as CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
Time frame: Up to approximately 4 years and 2 months
Progression-free Survival (PFS)
PFS is defined as the time from the date of first dose to the date of first documentation of progressive disease or death, whichever comes first, as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
Time frame: Up to approximately 4 years and 2 months
Maximum Plasma Concentration (Cmax) for Sitravatinib
Time frame: Predose and up to 24 hours post dose on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 21 (C1D21); 21 days per cycle
Time to Maximum Plasma Concentration (Tmax) for Sitravatinib
Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Time Point (AUC(0-t)) for Sitravatinib
Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Clearance After Oral Administration (CL/F) for Sitravatinib
Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Area Under the Plasma Concentration-time Curve During the Dosing Interval (AUC(0-tau)) for Sitravatinib
Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Observed Accumulation Ratio (Ro) for AUC0-tau for Sitravatinib
Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation
Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
Observed Accumulation Ratio (Ro) for Cmax for Sitravatinib
Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation
Time frame: Predose and up to 24 hours post dose on C1D1 and C1D21; 21 days per cycle
This study enrolled participants across study centers in Australia and China.
| Milestone | Sitravatinib + Tislelizumab |
|---|---|
| Started | 216 |
| Completed | 0 |
| Not completed | 216 |
| Withdrew: Death | 158 |
| Withdrew: Sponsor decision | 31 |
| Withdrew: Withdrawal by subject | 11 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Physician decision | 1 |
| Withdrew: Rolled into extension study | 9 |
| Withdrew: Progressive disease | 1 |
Number of participants with treatment-emergent AEs (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs; TEAE was defined as an adverse event that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug(s) up to 30 days following last dose of study drug(s) or initiation of a new anticancer therapy, whichever occurs first.
| Participants | Sitravatinib + Tislelizumab |
|---|---|
| At least 1 TEAE | 216 |
| At least 1 SAE | 120 |
ORR is defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) as determined by the investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
| Percentage of participants | Sitravatinib + Tislelizumab |
|---|---|
| Cohort A: NSCLC | 4.3 (0.1 to 21.9) |
| Cohort B: NSCLC | 23.8 (8.2 to 47.2) |
| Cohort C: RCC | 66.7 (9.4 to 99.2) |
| Cohort D: RCC | 0.0 (0.0 to 70.8) |
| Cohort E: OC | 28.8 (17.8 to 42.1) |
| Cohort F: NSCLC | 18.2 (5.2 to 40.3) |
| Cohort G: Melanoma | 36.0 (18.0 to 57.5) |
| Cohort H: NSCLC | 60.0 (36.1 to 80.9) |
| Cohort I: NSCLC | 30.4 (13.2 to 52.9) |
DOR is defined as the time from the first determination of an objective response until the first documentation of progressive disease, whichever comes first, as assessed by the investigator using RECIST v1.1. Results are reported for cohorts with responders, defined as CR or PR. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
| Months | Sitravatinib + Tislelizumab |
|---|---|
| Cohort A: NSCLC | 3.1 (NA to NA) |
| Cohort B: NSCLC | 17.9 (2.9 to NA) |
| Cohort C: RCC | 11.4 (9.7 to NA) |
| Cohort E: OC | 5.6 (2.8 to 12.5) |
| Cohort F: NSCLC | 6.9 (3.4 to NA) |
| Cohort G: Melanoma | 19.1 (2.8 to NA) |
| Cohort H: NSCLC | 9.7 (5.6 to 15.9) |
| Cohort I: NSCLC | 8.1 (5.5 to NA) |
DCR is defined as the percentage of participants with best overall response as CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
| Percentage of participants | Sitravatinib + Tislelizumab |
|---|---|
| Cohort A: NSCLC | 78.3 (56.3 to 92.5) |
| Cohort B: NSCLC | 85.7 (63.7 to 97.0) |
| Cohort C: RCC | 100.0 (29.2 to 100.0) |
| Cohort D: RCC | 100.0 (29.2 to 100.0) |
| Cohort E: OC | 79.7 (67.2 to 89.0) |
| Cohort F: NSCLC | 90.9 (70.8 to 98.9) |
| Cohort G: Melanoma | 88.0 (68.8 to 97.5) |
| Cohort H: NSCLC | 85.0 (62.1 to 96.8) |
| Cohort I: NSCLC | 78.3 (56.3 to 92.5) |
PFS is defined as the time from the date of first dose to the date of first documentation of progressive disease or death, whichever comes first, as assessed by the investigator using RECIST v1.1. Efficacy was evaluated by cohort, as pre-specified in the statistical analysis plan.
| Months | Sitravatinib + Tislelizumab |
|---|---|
| Cohort A: NSCLC | 4.2 (2.7 to 5.8) |
| Cohort B: NSCLC | 7.0 (2.7 to 11.2) |
| Cohort C: RCC | 15.9 (11.1 to NA) |
| Cohort D: RCC | 2.7 (2.6 to NA) |
| Cohort E: OC | 4.1 (3.5 to 5.1) |
| Cohort F: NSCLC | 5.3 (4.1 to 8.2) |
| Cohort G: Melanoma | 6.7 (4.1 to 29.7) |
| Cohort H: NSCLC | 10.9 (5.1 to 15.3) |
| Cohort I: NSCLC | 5.4 (2.8 to 9.5) |
| nanograms/milliliter (ng/mL) | Sitravatinib + Tislelizumab |
|---|---|
| C1D1 | 49.49 ± 82.688 |
| C1D21 | 98.36 ± 68.908 |
| Hours (h) | Sitravatinib + Tislelizumab |
|---|---|
| C1D1 | 6.09 (2.0 to 24.8) |
| C1D21 | 6.08 (0.0 to 23.2) |
| h*ng/mL | Sitravatinib + Tislelizumab |
|---|---|
| C1D1 | 414.01 ± 115.833 |
| C1D21 | 1539.96 ± 83.010 |
| Liters/hour | Sitravatinib + Tislelizumab |
|---|---|
| C1D1 | 72.89 ± 148.368 |
| C1D21 | 58.30 ± 58.470 |
| h*ng/mL | Sitravatinib + Tislelizumab |
|---|---|
| C1D1 | 1050.57 ± 75.432 |
| C1D21 | 2058.23 ± 58.470 |
Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation
| Ratio | Sitravatinib + Tislelizumab |
|---|---|
| Observed Accumulation Ratio (Ro) for AUC0-tau for Sitravatinib | 1.83 (1.18 to 2.82) |
Presented as geometric mean ratio and confidence interval, transformed from the difference of least square means and confidence interval of the least square differences in the logarithmic scale by exponentiation
| Ratio | Sitravatinib + Tislelizumab |
|---|---|
| Observed Accumulation Ratio (Ro) for Cmax for Sitravatinib | 2.23 (1.69 to 2.95) |
Collected over From the first dose up to 30 days after the last dose of study drug; Up to approximately 4 years and 2 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitravatinib + Tislelizumab | 158/216 (73.1%) | 120/216 (55.6%) | 213/216 (98.6%) |
| Event | Sitravatinib + Tislelizumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 11/216 |
| PneumoniaInfections and infestations | 10/216 |
| DeathGeneral disorders | 9/216 |
| Abdominal painGastrointestinal disorders | 8/216 |
| PyrexiaGeneral disorders | 8/216 |
| VomitingGastrointestinal disorders | 7/216 |
| Small intestinal obstructionGastrointestinal disorders | 6/216 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/216 |
| AscitesGastrointestinal disorders | 4/216 |
| Intestinal obstructionGastrointestinal disorders | 4/216 |
| Event | Sitravatinib + Tislelizumab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 114/216 |
| Alanine aminotransferase increasedInvestigations | 101/216 |
| Aspartate aminotransferase increasedInvestigations | 97/216 |
| Weight decreasedInvestigations | 82/216 |
| HypertensionVascular disorders | 81/216 |
| HypothyroidismEndocrine disorders | 71/216 |
| Decreased appetiteMetabolism and nutrition disorders | 71/216 |
| NauseaGastrointestinal disorders | 67/216 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 63/216 |
| VomitingGastrointestinal disorders | 57/216 |
| Age, Continuous(Years) | Sitravatinib + Tislelizumab |
|---|---|
| Mean | 60.2 ± 11.03 |
| Sex: Female, Male(Participants) | Sitravatinib + Tislelizumab |
|---|---|
| Female | 103 |
| Male | 113 |
| Ethnicity (NIH/OMB)(Participants) | Sitravatinib + Tislelizumab |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 213 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Sitravatinib + Tislelizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 143 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 0 |
| White | 70 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Nov 2018 to primary completion in Jan 2023, 50 months.
Results were first posted in Jun 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitravatinib · Tislelizumab